CasNo.39262-14-1,(20S)-20-(β-D-Glucopyranosyloxy) 39262-14-1,(39262-14-1) Suppliers

5 Kilogram	FOB Price:USD 45.0000 -65.0000

Min.Order :5 Kilogram
Purity: >99%
Payment Terms : L/C,D/A,D/P,T/T

Keywords

Ginsenoside CK 20(S)-Protopanaxadiol 20-O-D-glucopyranoside b-D-Glucopyranoside

Quick Details

Appearance:White powder
Application:Cytosine (C) is one of the four main bases found in DNA and RNA, along with adenine, guanine, and thymine (uracil in RNA). Cytosine reagent is used in a wide variety of research applications, as an
PackAge:Brown vial or HDPE plastic bottle
ProductionCapacity:3000|Kilogram|Month
Storage:Cool Dry Place
Transportation:Bag or Drum

Superiority:

OEM Supply Superior Quality 99% Cytosine CAS 71-30-7

Basic Information:

Cytosine (C) is one of the four main bases found in DNA and RNA, along with adenine, guanine, and thymine (uracil in RNA).

Cytosine reagent is used in a wide variety of research applications, as an enzyme-substrate or precursor of effector molecules such as cytosine sugars.

Product Name:	Cytosine
Synonyms:	4-AMINO-2(1H)-PYRIMIDINONE;4-AMINO-2(1)-PYRIMIDONE;4-AMINO-2-PYRIMIDINOL;4-AMINO-2-OXO-1,2-DIHYDROPYRIMIDINE;4-AMINO-2-HYDROXYPYRIMIDINE;2-Oxy-4-amino pyrimidine;AURORA KA-682;CYTOSINE
CAS:	71-30-7
MF:	C4H5N3O
MW:	111.1

Details:

Molecular Formula	C36H62O8
Molar Mass	622.88
Density	1.19
Melting Point	181～183℃
Boling Point	723.1±60.0 °C(Predicted)
Specific Rotation(α)	(c, 1 in MeOH)+39
Solubility	Soluble in DMSO, pyridine, insoluble in petroleum ether, chloroform and other organic solvents.
Appearance	White powder
pKa	12.94±0.70(Predicted)
Storage Condition	2-8℃
MDL	MFCD07772261
Physical and Chemical Properties	White crystalline powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from ginseng rhizome, Gynostemma pentaphyllum.
In vitro study	Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects mainly by reducing inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and proinflammatory cytokines. Ginsenoside C-K suppresses the expression of proinflammatory cytokines by downregulating the activities of IRAK-1, MAPKs, IKK-α, and NF-κB in LPS-treated murine peritoneal macrophages. Ginsenoside C-K also suppresses the expression of iNOS and COX-2 by inhibiting NF-κB signaling in LPS-stimulated RAW264.7 cells. In zymosan-treated bone-marrow-derived macrophages (BMDMs) and RAW264.7 cells, Ginsenoside C-K inhibits inflammatory responses by negatively regulating the secretion of proinflammatory cytokines, the activation of MAPKs, and the generation of ROS. In addition, anti-inflammatory activity of Ginsenoside C-K has been observed in LPS-stimulated microglial cells. Ginsenoside C-K hinders inflammatory responses by controlling both the generation of ROS and the activities of MAPKs, NF-κB, and AP-1. Ginsenoside C-K, a major metabolite of ginsenosides in the gastrointestinal tract, inhibits NF-κB signaling in a PXR-dependent manner. Ginsenoside C-K is shown to promote recovery of dextran sulfate sodium (DSS) -induced colitis by suppressing NF-κB activation. Ginsenoside C-K significantly reduces TNF-α-induced upregulation of IL-1β and iNOS mRNA levels, and restores the mRNA levels of PXR and CYP3A4 in LS174T cells. Ginsenoside C-K, one of the intestinal metabolites of 20(S)-protopanaxadiol derivatives, exhibits an inhibition against the activity of CYP2C9 in human liver microsomes with an IC 50 value of 32.0±3.6 μM, a weak inhibition against the activity of CYP2A6 in human liver microsomes with an IC 50 value of 63.6±4.2 μM, and an even weaker inhibition against the activity of CYP2D6 in human liver microsomes with an IC 50 value of more than 100 μM.
In vivo study	The weight of the collagen-induced arthritis (CIA) mice increases slowly and is significantly less than that of the normal DBA/1 mice beginning on d 3 after injection of the emulsion. Ginsenoside C-K (28, 56, and 112 mg/kg) mice recover their weight by d 32 after the emulsion injection. Ginsenoside C-K (56 and 112 mg/kg) and Methotrexate (MTX)-treated (2 mg/kg) mice show significantly increased body weight on d 50 as compared with CIA mice. Hind paw-swelling began on d 24 post-immunization. CIA mice are treated from d 28 to d 50. Arthritis scores are measured every 4 d beginning on d 24. Ginsenoside C-K (56 and 112 mg/kg) significantly reduces the arthritis scores of the mice on d 51.